ClariVest Asset Management’s Intellia Therapeutics NTLA Stock Holding History

ClariVest Asset Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-10,151	Closed	-$310K	–	894
2023 Q4	$310K	Buy	10,151 +2,770	+38%	+$79.6K	0.02%	376
2023 Q3	$233K	Hold	7,381	–	–	0.01%	368
2023 Q2	$301K	Sell	7,381 -500	-6%	-$20.3K	0.02%	363
2023 Q1	$294K	Buy	7,881 +22	+0.3%	+$863	0.01%	412
2022 Q4	$274K	Sell	7,859 -13	-0.2%	-$618	0.01%	417
2022 Q3	$441K	Sell	7,872 -22	-0.3%	-$1.36K	0.02%	375
2022 Q2	$408K	Hold	7,894	–	–	0.02%	404
2022 Q1	$574K	Sell	7,894 -4	-0.1%	-$339	0.02%	364
2021 Q4	$933K	Sell	7,898 -514	-6%	-$64.4K	0.03%	333
2021 Q3	$1.13M	Buy	8,412 +4,718	+128%	+$714K	0.04%	303
2021 Q2	$598K	Buy	+3,694	New	+$288K	0.02%	403
2017 Q2	–	Sell	-6,412	Closed	-$90K	–	704
2017 Q1	$90K	Sell	6,412 -2,665	-29%	-$35.8K	﹤0.01%	565
2016 Q4	$119K	Sell	9,077 -267	-3%	-$4.01K	﹤0.01%	522
2016 Q3	$159K	Buy	+9,344	New	+$181K	﹤0.01%	521

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClariVest Asset Management's NTLA Position: Q1 2024 in Review

ClariVest Asset Management sold out of Intellia Therapeutics (NTLA) in Q1 2024, closing a stake of 10,151 shares — an estimated $310K sold.

ClariVest Asset Management first reported a position in NTLA in Q3 2016 and held it in 14 quarters. The position peaked at $1.13M in Q3 2021. 284 funds tracked by Wall St. Rank hold NTLA as of Q1 2024.

ClariVest Asset Management reported no remaining Intellia Therapeutics position as of Q1 2024 after selling out during the quarter.
ClariVest Asset Management sold 10,151 Intellia Therapeutics shares in Q1 2024, an estimated $310K.
ClariVest Asset Management first reported a position in Intellia Therapeutics in Q3 2016 and held it in 14 quarters.
ClariVest Asset Management's Intellia Therapeutics position peaked at $1.13M in Q3 2021.
284 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2024.

Based on ClariVest Asset Management's 13F filing for Q1 2024, filed 7 May 2024.